Template:Anderson2016 table2: Difference between revisions

From Embryology
mNo edit summary
mNo edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
{|
{|
! colspan=3|Table 2. Summary of Timing (Post Fertilization) of Susceptibility to a Drug-Induced Malformation
|+ colspan=3|'''Table 2. Summary of Timing (Post Fertilization) of Susceptibility to a Drug-Induced Malformation'''
|-bgcolor="CEDFF2"
|-bgcolor="CEDFF2"
! width=300px|Lesion
! width=300px|Lesion
Line 118: Line 118:
! colspan=3|Notes
! colspan=3|Notes
|-
|-
| colspan=3|For approximate clinical Gestational Age {{GA}} add 2 weeks; number in brackets is mouse equivalent.
| colspan=3|For approximate clinical Gestational Age {{GA}} add 2 weeks; number in brackets is mouse equivalent. Data Reference<ref name=Anderson2016>{{Ref-Anderson2016}}</ref>
 
| colspan=3|'''Links:''' {{heart}} | {{abnormal development}} | {{timeline}} | [[:Category:Timeline]]
Reference: {{Ref-Anderson2016}}
|}<noinclude>[[Category:Heart]][[Category:Abnormal Development]][[Category:Table]][[Category:Timeline]]</noinclude>
|}<noinclude>[[Category:Heart]][[Category:Abnormal Development]][[Category:Table]][[Category:Timeline]]</noinclude>
{{Anderson2016 collapsetable2}}
{{Anderson2016 collapsetable2}}

Latest revision as of 17:00, 11 May 2018

Table 2. Summary of Timing (Post Fertilization) of Susceptibility to a Drug-Induced Malformation
Lesion Start of Susceptibility
to Malformation
End of Susceptibility
to Malformation
Interatrial communications
Oval fossa defect 6 weeks (E13.5) Term
Sinus venosus defect 8 weeks 12 weeks
Coronary sinus defect 8 weeks Term
Vestibular defect 7 weeks 8 weeks
Ventricular Septal Defect
Muscular 8 weeks Difficult to predict
Perimembranous 6 weeks 8 weeks
Doubly committed 7 weeks 8 weeks
Atrioventricular Septal Defect
Ostium primum 5 weeks 6 weeks
“Complete” 5 weeks 6 weeks
Aortic coarctation
With VSD 5 weeks 8 weeks
With intact ventricular septum 8 weeks Term
Double Outlet Right Ventricle 6 weeks 8 weeks
Transposition of Great Arteries 6 weeks 8 weeks
Ebstein’s malformation 6 weeks 8 weeks
Hypoplastic left heart syndrome
With mitral atresia 5 weeks 8 weeks
With mitral stenosis 8 weeks Term
Pulmonary atresia
With VSD 6 weeks 8 weeks
With intact ventricular septum 8 weeks Term
Other
Functionally single ventricle 5 weeks 6 weeks
Tetralogy of Fallot 7 weeks 8 weeks
Totally anomalous pulmonary venous return 8 weeks 12 weeks
Tricuspid atresia 5 weeks 6 weeks
Common arterial trunk 5 weeks 7 weeks
Bicuspid aortic valve 6 weeks Term
Notes
For approximate clinical Gestational Age GA add 2 weeks; number in brackets is mouse equivalent. Data Reference[1] Links: heart | abnormal development | timeline | Category:Timeline
Table 2. Summary of Timing (Post Fertilization) of Cardiac Susceptibility to a Drug-Induced Malformation  
Lesion Start of Susceptibility
to Malformation
End of Susceptibility
to Malformation
Interatrial communications
Oval fossa defect 6 weeks (E13.5) Term
Sinus venosus defect 8 weeks 12 weeks
Coronary sinus defect 8 weeks Term
Vestibular defect 7 weeks 8 weeks
Ventricular Septal Defect
Muscular 8 weeks Difficult to predict
Perimembranous 6 weeks 8 weeks
Doubly committed 7 weeks 8 weeks
Atrioventricular Septal Defect
Ostium primum 5 weeks 6 weeks
“Complete” 5 weeks 6 weeks
Aortic coarctation
With VSD 5 weeks 8 weeks
With intact ventricular septum 8 weeks Term
Double Outlet Right Ventricle 6 weeks 8 weeks
Transposition of Great Arteries 6 weeks 8 weeks
Ebstein’s malformation 6 weeks 8 weeks
Hypoplastic left heart syndrome
With mitral atresia 5 weeks 8 weeks
With mitral stenosis 8 weeks Term
Pulmonary atresia
With VSD 6 weeks 8 weeks
With intact ventricular septum 8 weeks Term
Other
Functionally single ventricle 5 weeks 6 weeks
Tetralogy of Fallot 7 weeks 8 weeks
Totally anomalous pulmonary venous return 8 weeks 12 weeks
Tricuspid atresia 5 weeks 6 weeks
Common arterial trunk 5 weeks 7 weeks
Bicuspid aortic valve 6 weeks Term

Notes: For approximate clinical Gestational Age GA add 2 weeks; number in brackets is mouse equivalent.

Reference: Anderson RH. Teratogenecity in the setting of cardiac development and maldevelopment. (2016)